Prospective randomized clinical study of a new topical formulation for face wrinkle reduction and dermal regeneration.

Abstract

Listen

Translate article

A new topical formulation (TF) based on 3 main lifting components has been developed to reduce superficial facial wrinkles. Determine the effectiveness of this new TF in reducing superficial face wrinkles and restructuring the dermal matrix. Women, aged 30-65y.o. with moderate to severe crow's feet wrinkles were included. men; younger than 30 or older than 65years old; smokers. Patients received 15IU of botulinum toxin on crow's feet and 2 creams. Fifty patients (Group 1) applied the TP (Product A) and 50 (Group 2) a placebo (Product B). Assessments were made by digital macro-photography's, Antera 3D, and a patient satisfaction questionnaire. From April to June 2019, 100 women were enrolled in the study and were divided into two homogeneous groups. No major or minor side effects were reported. In group 1, wrinkles, texture, static and dynamic crow's feet wrinkles improved significantly at 3 and 6months. Patients were very satisfied at 3months and satisfied at 6months. In group 2, wrinkles and texture improved significantly at 3months but did not improve at 6months. Static and dynamic crow's feet wrinkles improved significantly at 1 and 3months but did not improve significantly at 6months. Our prospective and randomized study has shown that the new TF is safe and effective in reducing superficial face wrinkles and producing dermal regeneration. It, therefore, prolongs the duration of the botulinum toxin. Further controlled study would be necessary to compare the new TF to neurotoxin treatment, or its action alone.